Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 12-Month High at $140.28

Zealand Pharma A/S (OTCMKTS:ZLDPFGet Free Report)’s stock price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $140.28 and last traded at $136.04, with a volume of 1582 shares changing hands. The stock had previously closed at $128.80.

Analysts Set New Price Targets

ZLDPF has been the subject of a number of recent research reports. Cantor Fitzgerald assumed coverage on Zealand Pharma A/S in a research report on Tuesday, May 21st. They set an “overweight” rating for the company. BTIG Research began coverage on shares of Zealand Pharma A/S in a research report on Thursday, March 7th. They set a “buy” rating on the stock.

Read Our Latest Stock Report on ZLDPF

Zealand Pharma A/S Stock Up 5.6 %

The stock has a fifty day moving average price of $98.00 and a 200-day moving average price of $85.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.28 and a current ratio of 12.30. The firm has a market cap of $7.01 billion, a PE ratio of -74.75 and a beta of 0.97.

Zealand Pharma A/S (OTCMKTS:ZLDPFGet Free Report) last announced its quarterly earnings results on Thursday, May 16th. The company reported ($0.54) earnings per share (EPS) for the quarter. The company had revenue of $2.20 million during the quarter. Zealand Pharma A/S had a negative net margin of 213.77% and a negative return on equity of 36.96%. Research analysts expect that Zealand Pharma A/S will post -2.43 EPS for the current year.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Featured Articles

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.